Breast Cancer Research and Treatment

, Volume 31, Issue 1, pp 95–105 | Cite as

Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells

  • Colin K. W. Watts
  • Kimberley J. E. Sweeney
  • Andrea Warlters
  • Elizabeth A. Musgrove
  • Robert L. Sutherland
Article

Abstract

The molecular mechanisms by which antiestrogens inhibit breast cancer cell proliferation are not well understood. Using cultured breast cancer cell lines, we studied the effects of antiestrogens on proliferation and cell cycle progression and used this information to select candidate cell cycle regulatory genes that are potential targets for antiestrogens. Under estrogen- and serum-free conditions antiestrogens inhibited proliferation of MCF-7 cells stimulated with insulin. Cells were blocked at a point in G1 phase. These effects are comparable with those in serum- and estrogen-containing medium and were also seen to a lesser degree in nude mice bearing MCF-7 tumors. Similar observations with other peptide mitogens suggest that the process inhibited by antiestrogens is common to estrogen and growth factor activated pathways. Other studies have identified G1 cyclins as potential targets for growth factor and steroid hormone/steroid antagonist regulation of breast epithelial cell proliferation. In MCF-7 cells growing in the presence of fetal calf serum, cyclin D1 mRNA was rapidly down-regulated by steroidal and nonsteroidal antiestrogens by an apparently estrogen receptor mediated mechanism. Cyclin D1 gene expression was maximally inhibited before effects on entry into S phase and inhibition was therefore not merely a consequence of changes in cell cycle progression. Together with data on the effects of antiestrogens in serum-free conditions [1], these results suggest down-regulation of cyclin D1 by antiestrogens may be a general phenomenon in estrogen receptor-positive breast cancer cells, independent of culture conditions and class of antiestrogen. These observations are compatible with the hypothesis that reductions in cyclin D1 levels may mediate in part the action of antiestrogens in blocking entry of cells into S phase.

Key words

antiestrogens cell proliferation cell cycle cyclins breast cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Musgrove EA, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW, Sutherland RL: Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13: 3577–3587, 1993Google Scholar
  2. 2.
    Lerner LJ, Jordan VC: Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 50: 4177–4189, 1990Google Scholar
  3. 3.
    Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1–15, 71-85, 1992Google Scholar
  4. 4.
    Wakeling AE, Bowler J: Steroidal pure antioestrogens. J Endocrinol 112: R7-R10, 1987Google Scholar
  5. 5.
    Wakeling AE: The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 25: 1–9, 1993Google Scholar
  6. 6.
    Lippman ME, Bolan G: Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256: 592–593, 1975Google Scholar
  7. 7.
    Lippman M, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long term tissue culture. Cancer Res 36: 4595–4601, 1976Google Scholar
  8. 8.
    Sutherland RL, Green MD, Hall RE, Reddel RR, Taylor IW: Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19: 615–621, 1983Google Scholar
  9. 9.
    Sutherland RL, Hall RE, Taylor IW: Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 43: 3998–4006, 1983Google Scholar
  10. 10.
    Taylor IW, Hodson PJ, Green MD, Sutherland RL: Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res 43: 4007–4010, 1983Google Scholar
  11. 11.
    Wakeling AE, Newboult E, Peters SW: Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J Mol Endocrinol 2: 225–234, 1989Google Scholar
  12. 12.
    Musgrove EA, Wakeling AE, Sutherland RL: Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res 49: 2398–2404, 1989Google Scholar
  13. 13.
    Reddel RR, Murphy LC, Sutherland RL: Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. Cancer Res 44: 2398–2405, 1984Google Scholar
  14. 14.
    Osborne CK, Boldt DH, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44: 1433–1439, 1984Google Scholar
  15. 15.
    Hunter T, Pines J: Cyclins and cancer. Cell 66: 1071–1074, 1991Google Scholar
  16. 16.
    Pines J: Cyclins and cyclin-dependent kinases: take your partners. Trends Biol Sci 18: 195–197, 1993Google Scholar
  17. 17.
    Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059–1065, 1993Google Scholar
  18. 18.
    Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344: 503–508, 1990Google Scholar
  19. 19.
    Matsushime H, Roussel MF, Ashmun RA, Sherr CJ: Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65: 701–713, 1991Google Scholar
  20. 20.
    Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman J, Kronenberg H, Arnold A: A novel cyclin encoded by abcl1-linked candidate oncogene. Nature 350: 512–515, 1991Google Scholar
  21. 21.
    Lew DJ, Dulic V, Reed SI: Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 66: 1197–1206, 1991Google Scholar
  22. 22.
    Musgrove EA, Lee CSL, Sutherland RL: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell Biol 11: 5032–5043, 1991Google Scholar
  23. 23.
    Taylor IW: A rapid single step staining technique for DNA analysis by flow microfluorimetry. J Histochem Cytochem 28: 1021–1024, 1980Google Scholar
  24. 24.
    Alexander IE, Clarke CL, Shine J, Sutherland RL: Progestin inhibition of progesterone receptor gene expression in human breast cancer cells. Mol Endocrinol 3: 1377–1386, 1989Google Scholar
  25. 25.
    Xiong Y, Connolly T, Futcher B, Beach D: Human D-type cyclin. Cell 65: 691–699, 1991Google Scholar
  26. 26.
    Musgrove EA, Sutherland RL: Steroids, growth factors and cell cycle controls in breast cancer. In: Lippman ME, Dickson RB (eds) Regulatory Mechanisms in Breast Cancer. Kluwer Academic Publishers, Boston, 1991, pp 305–331Google Scholar
  27. 27.
    Sutherland RL, Watts CKW, Ruenitz PC: Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor. Biochem Biophys Res Commun 140: 523–529, 1986Google Scholar
  28. 28.
    Reddel RR, Murphy LC, Sutherland RL: Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cellsin vitro. Cancer Res 43: 4618–4624, 1983Google Scholar
  29. 29.
    Osborne CK, Bolan G, Monaco ME, Lippman ME: Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci 73: 4536–4540, 1976Google Scholar
  30. 30.
    Brünner N, Bronzert D, Vindeløv LL, Rygaard K, Spang-Thomsen M, Lippman ME: Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grownin vitro and in nude mice. Cancer Res 49: 1515–1520, 1989Google Scholar
  31. 31.
    Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183–5187, 1988Google Scholar
  32. 32.
    Weatherill PJ, Wilson APM, Nicholson RI, Davies P, Wakeling AE: Interaction of the antioestrogen ICI 164384 with the oestrogen receptor. J Steroid Biochem 30: 263–266, 1988Google Scholar
  33. 33.
    Sutherland RL, Hall RE, Pang GYN, Musgrove EA, Clarke CL: Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 48: 5084–5091, 1988Google Scholar
  34. 34.
    Jordan VC, Clark ER, Allen KE: Structure activity relationships amongst non-steroidal antioestrogens. In: Sutherland RL, Jordan VC (eds) Nonsteroidal Antioestrogens. Academic Press, Sydney, 1981, pp 31–57Google Scholar
  35. 35.
    Coezy E, Borgna J, Rochefort H: Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42: 317–323, 1982Google Scholar
  36. 36.
    Sutherland RL, Murphy LC, Hall RE, Reddel RR, Watts CKW, Taylor IW: Effects of antioestrogens on human breast cancer cellsin vitro. Interactions with high affinity intracellular binding sites and effects on cell proliferation kinetics. In: Bresciani F, King RJB, Lippman ME, Namer M, Raynaud J-P (eds) Progress in Cancer Research and Therapy, Vol. 31. Raven Press, New York, 1984, pp 193–212Google Scholar
  37. 37.
    Ruenitz PC, Bagley JR, Watts CKW, Hall RE, Sutherland RL: Substituted-vinyl hydroxytriarylethylenes, 1-[4-[2-(diethylamino) ethoxy]phenyl]-1-(4-hydroxyphenyl)-2-phenylethylenes: synthesis and effects on MCF 7 breast cancer cell proliferation. J Med Chem 29: 2511–2519, 1986Google Scholar
  38. 38.
    Bignon E, Pons M, Crastes de Paulet A, Doré J-C, Gilbert J, Abecassis J, Miquel J-F, Ojasoo T, Raynaud J-P: Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth. J Med Chem 32: 2092–2103, 1989Google Scholar
  39. 39.
    Sutherland RL, Reddel RR, Green MD: Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur J Cancer Clin Oncol 19: 307–318, 1983Google Scholar
  40. 40.
    Jordan VC (ed) Estrogen/Antiestrogen Action and Breast Cancer Therapy. University of Wisconsin Press, Madison, 1986Google Scholar
  41. 41.
    Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocr Rev 11: 221–265, 1990Google Scholar
  42. 42.
    Musgrove EA, Sutherland RL: Effects of the progestin antagonist RU 486 on T-47D cell proliferation. Biochem Biophys Res Commun 195: 1184–1190, 1993Google Scholar
  43. 43.
    Vignon F, Bouton MM, Rochefort H: Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 146: 1502–1508, 1987Google Scholar
  44. 44.
    Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47: 4355–4360, 1987Google Scholar
  45. 45.
    Glover JF, Irwin JT, Darbre PD: Interaction of phenol red with estrogenic and antiestrogenic action on growth of human breast cancer cells ZR-75-1 and T-47-D. Cancer Res 48: 3693–3697, 1988Google Scholar
  46. 46.
    Wakeling AE: Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J Steroid Biochem 34: 183–188, 1989Google Scholar
  47. 47.
    Furuya Y, Kohno N, Fujiwara Y, Saitoh Y: Mechanisms of estrogen action on the proliferation of MCF-7 human breast cancer cells in an improved culture medium. Cancer Res 49: 6670–6674, 1989Google Scholar
  48. 48.
    Daly RJ, Darbre PD: Cellular and molecular events in loss of estrogen sensitivity in ZR-75 1 and T-47-D human breast cancer cells. Cancer Res 50: 5868–5875, 1990Google Scholar
  49. 49.
    Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci (USA) 89: 4037–4041, 1992Google Scholar
  50. 50.
    Pham TA, Elliston JF, Nawaz Z, McDonnell DP, Tsai M-J, O'Malley BW: Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci (USA) 88: 3125–3129, 1991Google Scholar
  51. 51.
    Philips A, Chalbos D, Rochefort P: Estradiol increases and anti-estrogens antagonize the growth factor-induced Activator Protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268: 14103–14108, 1993Google Scholar
  52. 52.
    Kyprianou N, English HF, Davidson NE, Isaacs JT: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162–166, 1991Google Scholar
  53. 53.
    Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812–821, 1993Google Scholar
  54. 54.
    Quelle DE, Ashmun RA, Shurtleff SA, Kato J-y, Bar-Sagi D, Roussel MF, Sherr CJ: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7: 1559–1571, 1993Google Scholar
  55. 55.
    Keyomarsi K, Pardee AB: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci (USA) 90: 1112–1116, 1993Google Scholar
  56. 56.
    Motokura T, Keyomarsi K, Kronenberg HM, Arnold A: Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 protooncogene. J Biol Chem 267: 20412–20415, 1992Google Scholar
  57. 57.
    Wong MSJ, Murphy LC: Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells. J Steroid Biochem Molec Biol 39: 39–44, 1991Google Scholar
  58. 58.
    Dubik D, Dembinski TC, Shiu RPC: Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 47: 6517–6521, 1987Google Scholar
  59. 59.
    Watson PH, Pon RT, Shiu RPC: Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51: 3996–4000, 1991Google Scholar
  60. 60.
    Musgrove EA, Lee CSL, Buckley MF, Sutherland RL: Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci (USA) (in press)Google Scholar
  61. 61.
    Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127–2133, 1993Google Scholar
  62. 62.
    Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FBJM, Devilee P, Cornelisse CJ, van de Vijver MJ, Mooi WJ, Michalides RJAM: Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 52: 5229–5234, 1992Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Colin K. W. Watts
    • 1
  • Kimberley J. E. Sweeney
    • 1
  • Andrea Warlters
    • 1
  • Elizabeth A. Musgrove
    • 1
  • Robert L. Sutherland
    • 1
  1. 1.Cancer Biology DivisionGarvan Institute of Medical Research, St Vincent's HospitalSydneyAustralia

Personalised recommendations